THANK YOU FOR SUBSCRIBING
In February 2020, Stilla closed €20m ($22m) in Series B funding round that brought in Chinese group TUS‐Holdings as a new investor, with active participation from existing investors Illumina Ventures, BNP Paribas Développement, Kurma Partners, Paris Saclay Seed Funds, LBO France, and Idinvest Partners.
FREMONT, CA: In the last twenty years, digital polymerase chain reaction (dPCR) technology has given hopes to have potential applications in genetic engineering, medical diagnostics, and cell biology.
In this context, Paris, France‐based life sciences company Stilla Technologies, is offering digital dPCR solutions for high‐precision genetic analysis.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Since 2016, the company has been targeting the $2‐billion digital PCR market offering research organizations with specialized in molecular biology and genetic analysis via its Naica System, a digital PCR solution that allows scientists to detect and quantify DNA mutations with precision. The system supports a vast range of genetic tests and molecular biology assays, including liquid biopsy tests for cancer diagnostics, pre‐natal testing, viral load quantification, and GMO detection.
Naica operates on the company’s genetic testing and nucleic acid quantification technology, Crystal Digital PCR, and can characterize multiple types of nucleic acids with its three‐color detection capability.
Stilla released the first generation of the system in 2016 and generated first revenues in 2017. The company also supports and advises its customers worldwide through a multidisciplinary R&D team, with expertise spanning from microfluidics to chemistry, including molecular biology and AI.
In February 2020, Stilla closed €20m ($22m) in Series B funding round that brought in Chinese group TUS‐Holdings as a new investor, with active participation from existing investors Illumina Ventures, BNP Paribas Développement, Kurma Partners, Paris Saclay Seed Funds, LBO France, and Idinvest Partners. The company is using the capital to continue its development efforts for its solutions.
Led by RémiDangla, CEO, Stilla Technologies has also addressed these unusual times by developing a highly sensitive SARS-CoV-2 detection kit, which is intended for the qualitative detection of reported conserved viral nucleic acid sequences, Nucleoprotein N (FAM) and ORF1ab (HEX).
Utilizing the same Crystal Digital PCR, the kit includes reagents, Sapphire chips, and COVID-19 positive and negative controls. As per the company, it has appeared as an alternative to the traditional qPCR technique. Tests indicate a specific detection of SARS-CoV-2 sequences down to 5 copies per 25µl reaction (equivalent to 0.2 cp/µl) for ORF1ab and for Nucleoprotein N: down to 7 copies per 25µl reaction (equivalent to 0.28 cp/µl)).
More in News